» Articles » PMID: 37685585

The Complexities of Diagnosis with Co-Existing Gaucher Disease and Hemato-Oncology-A Case Report and Review of the Literature

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Sep 9
PMID 37685585
Authors
Affiliations
Soon will be listed here.
Abstract

Hematological abnormalities are the most common early symptoms of Gaucher disease (GD), with an increased risk of hematopoietic system malignancies reported in patients with GD. GD may be associated with monoclonal and polyclonal gammopathies; however, the mechanism of association of GD with multiple myeloma (MM) remains uncertain. Enzyme replacement therapy (ERT) has been shown to improve patients' cytopenia and it seems to facilitate anti-myeloma therapy in patients with co-occurring GD and MM. Although it is necessary to demonstrate the deficiency of enzymatic activity, as well as using genetic tests to finally diagnose GD, due to changes in the blood count image, bone marrow biopsy is still a frequent element of the GD diagnosis procedure. The diagnosis of GD is often delayed, mainly due to the heterogeneity of the histopathological picture of bone marrow biopsy or overlapping hematological abnormalities. Unrecognized and untreated GD worsens the response of a patient with an oncological disease to targeted treatment. We present a literature review, inspired by the case of a Caucasian patient initially diagnosed with MM and later confirmed with comorbid GD type 1 (GD1). We would like to point out the problem of underdiagnosis and delay in patients with GD.

Citing Articles

Development of selective nanomolar cyclic peptide ligands as GBA1 enzyme stabilisers.

Katzy R, van Neer R, Ferraz M, Nicolai K, Passioura T, Suga H RSC Chem Biol. 2025; .

PMID: 39936129 PMC: 11808397. DOI: 10.1039/d4cb00218k.

References
1.
Beutler E, Saven A . Misuse of marrow examination in the diagnosis of Gaucher disease. Blood. 1990; 76(3):646-8. View

2.
Pandey M, Grabowski G . Immunological cells and functions in Gaucher disease. Crit Rev Oncog. 2013; 18(3):197-220. PMC: 3661296. DOI: 10.1615/critrevoncog.2013004503. View

3.
Morad S, Cabot M . Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 2012; 13(1):51-65. DOI: 10.1038/nrc3398. View

4.
Mistry P, Lukina E, Ben Turkia H, Shankar S, Feldman H, Ghosn M . Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results. Am J Hematol. 2021; 96(9):1156-1165. PMC: 8457136. DOI: 10.1002/ajh.26276. View

5.
Harder H, Eucker J, Zang C, Possinger K, Muller-Hocker J, Beutler E . Coincidence of Gaucher's disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria. Ann Hematol. 2000; 79(11):640-3. DOI: 10.1007/s002770000202. View